70 related articles for article (PubMed ID: 11037109)
21. Association between CBR1 polymorphisms and NSCLC in the Chinese population.
Guo Y; Shen Y; Xia Y; Gu J
Oncol Lett; 2017 Nov; 14(5):6291-6297. PubMed ID: 29113280
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of F18, a Derivative of Calanolide A, in Human Liver Microsomes and Cytosol.
Wu X; Zhang Q; Guo J; Jia Y; Zhang Z; Zhao M; Yang Y; Wang B; Hu J; Sheng L; Li Y
Front Pharmacol; 2017; 8():479. PubMed ID: 28769808
[TBL] [Abstract][Full Text] [Related]
23. Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis.
Penning TM
Chem Res Toxicol; 2017 Jan; 30(1):162-176. PubMed ID: 27806574
[TBL] [Abstract][Full Text] [Related]
24. Stereospecific Metabolism of the Tobacco-Specific Nitrosamine, NNAL.
Kozlovich S; Chen G; Lazarus P
Chem Res Toxicol; 2015 Nov; 28(11):2112-9. PubMed ID: 26452127
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.
Tebay LE; Robertson H; Durant ST; Vitale SR; Penning TM; Dinkova-Kostova AT; Hayes JD
Free Radic Biol Med; 2015 Nov; 88(Pt B):108-146. PubMed ID: 26122708
[TBL] [Abstract][Full Text] [Related]
26. Potential contributions of the tobacco nicotine-derived nitrosamine ketone (NNK) in the pathogenesis of steatohepatitis in a chronic plus binge rat model of alcoholic liver disease.
Zabala V; Tong M; Yu R; Ramirez T; Yalcin EB; Balbo S; Silbermann E; Deochand C; Nunez K; Hecht S; de la Monte SM
Alcohol Alcohol; 2015 Mar; 50(2):118-31. PubMed ID: 25618784
[TBL] [Abstract][Full Text] [Related]
27. The aldo-keto reductases (AKRs): Overview.
Penning TM
Chem Biol Interact; 2015 Jun; 234():236-46. PubMed ID: 25304492
[TBL] [Abstract][Full Text] [Related]
28. NNK reduction pathway gene polymorphisms and risk of lung cancer.
Modesto JL; Hull A; Angstadt AY; Berg A; Gallagher CJ; Lazarus P; Muscat JE
Mol Carcinog; 2015 Jun; 54 Suppl 1(Suppl 1):E94-E102. PubMed ID: 24976539
[TBL] [Abstract][Full Text] [Related]
29. Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes.
Matsumoto K; Hasegawa T; Koyanagi J; Takahashi T; Akimoto M; Sugibayashi K
Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):127-35. PubMed ID: 24659525
[TBL] [Abstract][Full Text] [Related]
30. Induction of carbonyl reductase 1 (CBR1) expression in human lung tissues and lung cancer cells by the cigarette smoke constituent benzo[a]pyrene.
Kalabus JL; Cheng Q; Jamil RG; Schuetz EG; Blanco JG
Toxicol Lett; 2012 Jun; 211(3):266-73. PubMed ID: 22531821
[TBL] [Abstract][Full Text] [Related]
31. Contributions of human enzymes in carcinogen metabolism.
Rendic S; Guengerich FP
Chem Res Toxicol; 2012 Jul; 25(7):1316-83. PubMed ID: 22531028
[TBL] [Abstract][Full Text] [Related]
32. Metabolism of bupropion by baboon hepatic and placental microsomes.
Wang X; Abdelrahman DR; Fokina VM; Hankins GD; Ahmed MS; Nanovskaya TN
Biochem Pharmacol; 2011 Aug; 82(3):295-303. PubMed ID: 21570381
[TBL] [Abstract][Full Text] [Related]
33. Genetic variability in the metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL).
Ter-Minassian M; Asomaning K; Zhao Y; Chen F; Su L; Carmella SG; Lin X; Hecht SS; Christiani DC
Int J Cancer; 2012 Mar; 130(6):1338-46. PubMed ID: 21544809
[TBL] [Abstract][Full Text] [Related]
34. Bupropion metabolism by human placenta.
Wang X; Abdelrahman DR; Zharikova OL; Patrikeeva SL; Hankins GD; Ahmed MS; Nanovskaya TN
Biochem Pharmacol; 2010 Jun; 79(11):1684-90. PubMed ID: 20109440
[TBL] [Abstract][Full Text] [Related]
35. Structural basis for substrate specificity in human monomeric carbonyl reductases.
Pilka ES; Niesen FH; Lee WH; El-Hawari Y; Dunford JE; Kochan G; Wsol V; Martin HJ; Maser E; Oppermann U
PLoS One; 2009 Oct; 4(10):e7113. PubMed ID: 19841672
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Prokopczyk B; Sinha I; Trushin N; Freeman WM; El-Bayoumy K
Chem Biol Interact; 2009 Feb; 177(3):173-80. PubMed ID: 19038236
[TBL] [Abstract][Full Text] [Related]
37. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.
Barski OA; Tipparaju SM; Bhatnagar A
Drug Metab Rev; 2008; 40(4):553-624. PubMed ID: 18949601
[TBL] [Abstract][Full Text] [Related]
38. Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol.
Atalla A; Breyer-Pfaff U; Maser E
Xenobiotica; 2000 Aug; 30(8):755-69. PubMed ID: 11037109
[TBL] [Abstract][Full Text] [Related]
39. Carbonyl reduction of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in cytosol of mouse liver and lung.
Atalla A; Maser E
Toxicology; 1999 Nov; 139(1-2):155-66. PubMed ID: 10614696
[TBL] [Abstract][Full Text] [Related]
40. Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta.
Atalla A; Maser E
Chem Biol Interact; 2001 Jan; 130-132(1-3):737-48. PubMed ID: 11306090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
